A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)

Trial Profile

A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Mar 2018

At a glance

  • Drugs Lasmiditan (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Acronyms SPARTAN
  • Sponsors CoLucid Pharmaceuticals; Eli Lilly
  • Most Recent Events

    • 21 Mar 2018 Status changed from active, no longer recruiting to completed.
    • 09 Sep 2017 According to an Eli Lilly media release, data from this study were presented at the 18th Congress of the International Headache Society (IHC) 2017.
    • 09 Sep 2017 Results presented in an Eli Lilly media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top